WO1992019234A2 - Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins - Google Patents
Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins Download PDFInfo
- Publication number
- WO1992019234A2 WO1992019234A2 PCT/US1992/002808 US9202808W WO9219234A2 WO 1992019234 A2 WO1992019234 A2 WO 1992019234A2 US 9202808 W US9202808 W US 9202808W WO 9219234 A2 WO9219234 A2 WO 9219234A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- caring
- substance
- alkyl
- individual
- dependent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Definitions
- the present invention relates to aminotetralins (I) which are useful as pharmacotherapies for treatment and prevention of substance abuse, both as a stand alone therapy and as an adjunct with simultaneous psychological or alternative pharmacological treatments.
- Substance abuse the use of chemicals for recreational mind altering purposes, represents such a serious and well known medical and social problem that it needs no documentation. This is true whether the addiction be physical or psychological. It is also true regardless of whether the drug is tobacco, a stimulant (***e), depressant (alcohol), opiate narcotic (heroin) or one of a number of other substance such as hallucinogens, synthetic opiate narcotics, anti-depressants, etc or designer drugs thereof. Most treatment and/or prevention of substance abuse involves
- Disulfram and methadone while useful, have not achieved a success rate as high as desirable. Further, a psychopharmaceutic for treatment/prevention is need for other substances of abuse.
- US Patent 3,751,420 discloses bicyclic aminotetralin like compounds with a double bond as the bond connecting the two rings rather than an aromatic ring and these compounds have an oxygenated function at C 7 not C 5 as in the present invention. These compounds are useful as analgesic muscle relaxants and also as antibiotics.
- J. Medicinal Chemistry 18, 362 (1975) discloses 2-amino-5-oxygenated aminotetralins but not having an alkyl group at C 1 . These compounds were disclosed as being dopamine receptor agonist and hence possibly useful in treatment of Parkinson disease.
- 5-hydroxytryptamine stimulating effect and useful in stimulating male sexual behavior as well as treating depression and pain.
- US Patents 4,800,204 and 4,935,429 disclose use of dopamine agonists for treatment of drug abuse, particularly for ***e and tobacco, respectively.
- the compounds used in the present invention are not dopamine agonists, they are members of a class known as preferential antagonists of dopamine presynaptic receptors.
- Schmeidenberg's Archiv. Pharmacol., 331, 234 (1986) describes the unique pharmacology of the class of compounds known as DA receptor antagonists with preferential action at presynaptic receptors.
- the compounds of the present invention are members of this class but have never been disclosed as being useful in treating substance abuse.
- J. Pharm. Sci., 67 880 (1978) discloses an N-cyclopropyl analog of the aminotetralins (I) of the present invention.
- the disclosed compounds were taught as being useful as local anesthetics.
- the compounds disclosed by the reference are preferential antagonists of dopamine presynaptic receptors as are the aminotetralins (I) of the present invention.
- the present invention is the use of certain aminotetralins (I) to prevent and treat substance abuse.
- R 2-1 and R 2-2 are me same or different and are -H or C 1 -C 5 alkyl;
- R 5 is -H, C 1 -C 3 alkyl or -CO-R 5-1 where R 5-1 is C j 1C 3 alkyl or - ⁇ , and pharmaceutically acceptable anion salts thereof.
- Also disclosed is a method of reducing ***e use in an individual using ***e which comprises administering to the ***e using individual an effective amount of an aminotetralin of formula (I) where R 1 , R 2-1 , R 2-2 and R 5 are as defined above and pharmaceutically acceptable anion salts thereof.
- aminotetralins (+)-cis-(1S,2R)-5-methoxy-1-methyl-2-(n-propylamino)tetralin and(+)-cis-(1S,2R)-5-methoxy-1-methyl-2-(di-n-propylamino)tetralin are known, see US Patent 4,876,284.
- aminotetralins (I) are useful as pharmacotherapies for treatment and prevention of substance abuse, both as a stand alone therapy and as an adjunct with simultaneous psychological or alternative pharmacological treatments.
- the aminotetralins (I) of the present invention are useful in a number of different ways in caring for individuals involved with substance abuse or at risk of becomming involved.
- Caring as used in this patent includes both treatment of existing situations as well as preventing future substance abuse.
- caring is treating an individual who is dependent (either physically or psychologically) on a substance.
- caring is preventing an individual who is recreationally using, but not dependent upon a substance, from becomming dependent on the same or other substances of abuse.
- caring is preventing an individual who was previously, but not now, dependent from again becomming dependent on a substance.
- caring is preventing individuals who have no history of substance abuse but from whos life styles and activities clinicians believe are at risk of using substance for recreational purposes and/or becomming dependent on various substances.
- Treatable substances (drugs) of abuse include ***e, opiate narcotics, barbituates, amphetamines, tobacco, alcohol, hallucinogens, marihuana. More specifically these agents include ***e, heroin, codeine, morphine, meperidine, alcohol, tobacco, amphetamine, MDA, LSD, PCP, marihuana, amphetamine and methamphetamine.
- the most commonly used abused substances for which the method of the present invention is useful are ***e, heroin, alcohol, cigarettes, marihuana, PCP, amphetamine and methamphetamine.
- the aminotetralins (I) are administed intravenously, intramuscularly, or orally.
- An effective amount of the aminotetralins (I) is from about 200 mg/day to about 20 g/day, preferrably from about 500 mg/day to about 5 g/day.
- Intramuscular depot preparations are prepared in larger quantities for long term administration.
- Oral preparations in tablets, capsule, solution and suspension forms or as powders to be mixed in food are useful with doses of about 500 mg/day to about 15 g/day total, but more preferrably in the range of about 1 to about 3 g/day.
- aminotetralins (I) are not themselves addicting (individuals do not become dependent on them).
- the aminotetralins (I) are amines, and as such form acid addition salts when reacted with acids of sufficient strength.
- Pharmaceutically acceptable salts include salts of both inorganic and organic acids. The pharmaceutically acceptable salts are preferred over the corresponding free aminotetralins (I) since they produce compounds which are more water soluble and more crystalline.
- the preferred pharmaceutically acceptable salts include salts of the following acids methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, CH 3 -(CH 2 ) n -COOH where n is 0 thru 4, HOOC-(CH 2 )n-COOH where n is as defined above.
- variable substituents in addition to expressly defined structural features. These variable substituents are identified by a letter or a letter followed by a numerical subscript, for example, "Z 1 " or "R i " where "i” is an integer.
- variable substituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parentheses.
- each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses.
- both R i and R j are bonded to the preceding carbon atom.
- C i For these aminotetralins with an established system of carbon atom numbering, the carbon atoms are designated as C i , where "i" is the integer corresponding to the carbon atom number.
- C 6 represents the 6 position or carbon atom number in the molecule as traditionally designated by those skilled in the art.
- R 6 represents a variable substituent (either monovalent or bivalent) at the C 6 position.
- a rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic compound.
- -C(X 1 )(X 2 )- me two substituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial.
- the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the plane (axial), one substituent is always above the other.
- a substituent (X 1 ) which is "below” another substituent (X 2 ) will be identified as being in the alpha (a) configuration and is identified by a broken, dashed or dotted line attachment to the carbon atom, i.e., by the symbol “ ⁇ " or "!.
- the corresponding substituent attached “above” (X 2 ) the other (X 1 ) is identified as being in the beta ( ⁇ ) configuration and is indicated by an unbroken line attachment to the carbon atom.
- the carbon atom content of variable substituents is indicated in one of two ways.
- the first method uses a prefix to the entire name of the variable such as "C 1 -C 4 ", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable.
- the prefix is separated from the variable by a space.
- C 1 -C 4 alkyl represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given).
- the prefix indicates the entire carbon atom content of the variable being defined.
- C 2 -C 4 alkoxycarbonyl describes a group CH 3 -(CH 2 ) n -O-CO- where n is zero, one or two.
- the carbon atom content of only each portion of the definition is indicated separately by enclosing the "C i -C j " designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined.
- C 1 -C 3 )alkoxycarbonyl has the same meaning as C 2 -C 4 alkoxycarbonyl because the "C 1 -C 3 " refers only to the carbon atom content of the alkoxy group.
- C 2 -C 6 alkoxyalkyl and (C 1 -C 3 )alkoxy(C 1 -C 3 )alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms
- the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms.
- Caring refers to (1) treating an individual who is presently dependent on a substance, (2) preventing an individual who is using a substance from becomming dependent on that substance,
- Use refers to the situation where an individual uses a substance, is not dependent in any way on the substance and controls his/her own actions whether or not the use causes any physical or psychological harm or injury to the individual. Examples include an individual who socially takes a drink of wine once a month, an individual who smokes marihuana once a month or an individual who has a couple of beers. All these individuals are using a substance for recreational purposes, are not dependent on that substance and can stop, its use, if so desired.
- Abuse refers to the situation where an individual is dependent on a substance either physically or psychologically and and can not discontinue its use whether or not the use causes any physical or psychological harm or injury to the individual. Examples include, "heroin addicts”, smokers of tobacco who "can not quit” and alcoholics. All these individuals are using a substance for recreational purposes, are dependent on that substance and can not stop its use.
- Psychological dependence refers to the condition where the individual who has been using a substance wants and/or seeks the substance but does not have any other directly observable withdrawl symptoms.
- Reducing as used in this patent means either or both of using fewer times in a given period of time and/or using less of an amount of a substance (***e) at each use with the over all result of a decrease in the amount of substance used per unit time. This may include no use at all but is not limited to that situation.
- Alcohol refers to ethyl alcohol.
- Tobacco refers to cigarettes, pipe tobacco, cigars, chewing tobacco.
- LSD refers to lysergic acid diethylamide.
- MDA refers to 3,4-methylenedioxyamphetamine.
- PCP refers to phencyclidine
- Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
- Marihuana refers, and included, any species and any form of Cannabis whether the vegetable material or extract thereof containing the pharmacologically active cannabinols.
- a 60 kg, 32 year old female just admitted to a hospital for prolonged ***e abuse is put on a chronic intravenous infusion of 30 mg/hr of (+)-cis-(1S,2R)-5-methoxy-1-methyl-2-(n-propylamino)tetralin 24 - 48 hours after which she is given 1 gm intramuscular injections 4 times a day for 30 days. She is then switched to 3 gm oral of the same item, 4 times/day for the next 3 to 24 months or until she was sufficiently recovered to no longer require treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4511382A JPH06506951A (en) | 1991-04-26 | 1992-04-13 | Substance abuse treatment/prevention methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69323891A | 1991-04-26 | 1991-04-26 | |
US693,238 | 1991-04-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1992019234A2 true WO1992019234A2 (en) | 1992-11-12 |
WO1992019234A3 WO1992019234A3 (en) | 1993-01-07 |
Family
ID=24783880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/002808 WO1992019234A2 (en) | 1991-04-26 | 1992-04-13 | Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0581865A1 (en) |
JP (1) | JPH06506951A (en) |
AU (1) | AU1915192A (en) |
CA (1) | CA2106197A1 (en) |
WO (1) | WO1992019234A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102395558A (en) * | 2009-02-16 | 2012-03-28 | 雅培股份有限两合公司 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846741B2 (en) | 2011-11-18 | 2014-09-30 | Abbvie Inc. | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8853196B2 (en) | 2011-08-05 | 2014-10-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8957089B2 (en) | 2008-04-01 | 2015-02-17 | AbbVie Deutschland GmbH & Co. KG | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9586942B2 (en) | 2013-10-17 | 2017-03-07 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9586945B2 (en) | 2013-10-17 | 2017-03-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0064964A1 (en) * | 1981-05-08 | 1982-11-17 | Astra Läkemedel Aktiebolag | Therapeutically useful 1-alkyl-2-aminotetralin derivatives |
US4800204A (en) * | 1987-05-07 | 1989-01-24 | Mueller Peter S | Method of controlling tobacco use |
US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
US4994486A (en) * | 1989-05-31 | 1991-02-19 | Abbott Laboratories | Dopaminergic compounds |
-
1992
- 1992-04-13 JP JP4511382A patent/JPH06506951A/en active Pending
- 1992-04-13 AU AU19151/92A patent/AU1915192A/en not_active Abandoned
- 1992-04-13 CA CA002106197A patent/CA2106197A1/en not_active Abandoned
- 1992-04-13 EP EP92911383A patent/EP0581865A1/en not_active Withdrawn
- 1992-04-13 WO PCT/US1992/002808 patent/WO1992019234A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0064964A1 (en) * | 1981-05-08 | 1982-11-17 | Astra Läkemedel Aktiebolag | Therapeutically useful 1-alkyl-2-aminotetralin derivatives |
US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
US4800204A (en) * | 1987-05-07 | 1989-01-24 | Mueller Peter S | Method of controlling tobacco use |
US4994486A (en) * | 1989-05-31 | 1991-02-19 | Abbott Laboratories | Dopaminergic compounds |
Non-Patent Citations (5)
Title |
---|
Alcohol, vol. 7, no. 3, May/June 1990, Pergamon Press plc, (US), G.F. KOOB et al.: "Pharmacology of drug self-administration", pages 193-197, see page 195 * |
European Journal of Pharmacology, vol. 182, no. 2, 3 July 1990, Elsevier Science Publishers B.V. (Biomedical Division), M.F. PIERCEY et al.: "Electrophysiological effects of dopamine autoreceptor antagonists, (+)-AJ 76 and (+)-UH 232", pages 219-226, see whole document * |
J. Med. Chem., vol. 25, no. 3, 1982, American Chemical Society, D.S. FRIES et al.: "Aminotetralins as narcotic antagonists. 2. Synthesis and opiate-related activity of 1-phenyl-3-aminotetralins", pages 216-220, see whole document * |
Journal of Neural Transmission, vol. 65, no. 1, 1986, Springer-Verlag, K. SVENSSON et al.: "(+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors", pages 1-27, see whole document * |
Psychopharmacology, vol. 107, no. 1, May 1992, Springer-Verlag, (Berlin, DE), P.M. CALLAHAN et al.: "Effects of the putative dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 on the discriminative stimulus properties of ***e", pages 73-77, see whole document * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957089B2 (en) | 2008-04-01 | 2015-02-17 | AbbVie Deutschland GmbH & Co. KG | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
CN102395558A (en) * | 2009-02-16 | 2012-03-28 | 雅培股份有限两合公司 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy |
CN102395558B (en) * | 2009-02-16 | 2015-09-02 | Abbvie公司 | Aminotetralin derivatives, the pharmaceutical composition containing described Aminotetralin derivatives and purposes in the treatment thereof |
US9096619B2 (en) | 2009-02-16 | 2015-08-04 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9067871B2 (en) | 2009-02-16 | 2015-06-30 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9238619B2 (en) | 2010-08-13 | 2016-01-19 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9227930B2 (en) | 2010-08-13 | 2016-01-05 | Abbvie Inc. | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8853196B2 (en) | 2011-08-05 | 2014-10-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846741B2 (en) | 2011-11-18 | 2014-09-30 | Abbvie Inc. | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9586942B2 (en) | 2013-10-17 | 2017-03-07 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9586945B2 (en) | 2013-10-17 | 2017-03-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
Also Published As
Publication number | Publication date |
---|---|
EP0581865A1 (en) | 1994-02-09 |
AU1915192A (en) | 1992-12-21 |
WO1992019234A3 (en) | 1993-01-07 |
JPH06506951A (en) | 1994-08-04 |
CA2106197A1 (en) | 1992-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Robson | Therapeutic aspects of cannabis and cannabinoids | |
EP1327447B1 (en) | Noribogaine in the treatment of pain and drug addiction | |
Bruera et al. | Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer | |
US10653662B2 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
US8017623B2 (en) | Dextromethorphan hydrochloride | |
EP1617832B1 (en) | Compositions for affecting weight loss | |
WO1992019234A2 (en) | Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins | |
CN101272776B (en) | Application of carbamic acid ester for treating substance abuse related disease | |
EP0563336B1 (en) | Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
US20090042972A1 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
US5846975A (en) | Use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence | |
Batterman | Clinical effectiveness and safety of a new synthetic analgesic drug, demerol | |
US20090042971A1 (en) | Method of using low-dose doxepin for the improvement of sleep | |
Gold et al. | Efficacy of clonidine in opiate withdrawal: a study of thirty patients | |
US6858648B2 (en) | Laetispicine and laetispicine analogues, methods of use and preparation | |
AU659941B2 (en) | Agents for treating substance abuse disorders | |
EP1292305B1 (en) | Use of l-threo methylphenidate for the manufacture of a medicament for the treatment of psychotic disorders | |
Challoner et al. | Pentazocine (Talwin®) intoxication: Report of 57 cases | |
Nicholson et al. | Modulation of catecholamine transmission and sleep in man | |
EP0900082B1 (en) | Use of pyridyl- and pyrimidyl-piperazines for the manufacture of a medicament for the treatment of substance abuse disorders | |
JP2015522082A (en) | Condensed benzazepine for the treatment of Tourette syndrome | |
Kramer | Heroin in the treatment of morphine addiction | |
EP0013110B1 (en) | Analgesic composition | |
Resnick | Prospects, problems, side effects, and safety of narcotic antagonists | |
Bovill | Opioid detoxification under anaesthesia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992911383 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2106197 Country of ref document: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992911383 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992911383 Country of ref document: EP |